UroGen Pharma Ltd. Stock

Equities

URGN

IL0011407140

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:01 2024-05-16 pm EDT 5-day change 1st Jan Change
13.19 USD -4.28% Intraday chart for UroGen Pharma Ltd. +1.70% -12.07%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 93.99M Sales 2025 * 149M Capitalization 477M
Net income 2024 * -128M Net income 2025 * -108M EV / Sales 2024 * 4.14 x
Net cash position 2024 * 88.52M Net cash position 2025 * 308M EV / Sales 2025 * 1.13 x
P/E ratio 2024 *
-3.67 x
P/E ratio 2025 *
-4.48 x
Employees 204
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.28%
More Fundamentals * Assessed data
Dynamic Chart
Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating MT
Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024
Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M MT
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy CI
UroGen Pharma Ltd. Reports New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer CI
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto MT
Oppenheimer Adjusts UroGen Pharma Price Target to $34 From $35, Maintains Outperform Rating MT
Transcript : UroGen Pharma Ltd., Q4 2023 Earnings Call, Mar 14, 2024
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug MT
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $32, Maintains Outperform Rating MT
More news
1 day-4.28%
1 week+1.70%
Current month-4.56%
1 month-8.97%
3 months-31.76%
6 months+10.01%
Current year-12.07%
More quotes
1 week
10.60
Extreme 10.6001
14.05
1 month
10.60
Extreme 10.6001
14.89
Current year
10.60
Extreme 10.6001
19.87
1 year
8.69
Extreme 8.69
24.13
3 years
4.85
Extreme 4.85
24.13
5 years
4.85
Extreme 4.85
39.88
10 years
4.85
Extreme 4.85
69.57
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 19-01-02
Director of Finance/CFO 47 21-07-31
Compliance Officer 52 20-09-08
Members of the board TitleAgeSince
Chairman 74 12-09-30
Director/Board Member 70 17-09-30
Director/Board Member 67 17-05-15
More insiders
Date Price Change Volume
24-05-16 13.21 -4.14% 207,409
24-05-15 13.78 +6.25% 619,719
24-05-14 12.97 -0.77% 481,646
24-05-13 13.07 +2.59% 572,307
24-05-10 12.74 -1.77% 351,013

Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT

More quotes
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.21 USD
Average target price
38 USD
Spread / Average Target
+187.66%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW